CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer

Comment: CDK4/6 inhibitors in advanced breast cancer

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma

Ovarian highlights from ESMO 2019

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation

Comment: Osimertinib for EGFR-mutation positive NSCLC

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer